Pancreatic cancer drug Afinitor by Novartis AG's has been approved by the U.S. FDA for a rare type of pancreatic cancer that has few treatment options, reports Reuters. The Swiss drugmaker said in a statement, "Data show Afinitor delays tumor growth and reduces risk of disease progression in patients with advanced neuroendocrine tumours (NET) of pancreatic origin."
"This marks the first approval of a treatment for this patient population in the United States in nearly 30 years," they added, Reuters reports.
Pancreatic Cancer Drug Afinitor Approved By FDA
A former senior adviser at the National Institute of Allergy and Infectious Diseases is facing charges...
When Bug got home from school one winter afternoon in late 2024, his mother was on...
A Pennsylvania court on Monday said that the state’s constitution guarantees a right to abortion while...
Donald Trump has selected Erica Schwartz to lead the Centers for Disease Control and Prevention (CDC),...
